相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk
Jean-Claude Tardif et al.
EUROPEAN HEART JOURNAL (2022)
Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients
Camilla Ditlev Lindhardt Johannesen et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)
Circulating angiopoietin-like proteins in metabolic-associated fatty liver disease: a systematic review and meta-analysis
Yani Ke et al.
LIPIDS IN HEALTH AND DISEASE (2021)
Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia
Daniel Gaudet et al.
EUROPEAN HEART JOURNAL (2020)
Evinacumab for Homozygous Familial Hypercholesterolemia
Frederick J. Raal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Evinacumab in Patients with Refractory Hypercholesterolemia
Robert S. Rosenson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Lipid-Lowering Agents Targets Beyond PCSK9
Robert A. Hegele et al.
CIRCULATION RESEARCH (2019)
N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels
Veronica J. Alexander et al.
EUROPEAN HEART JOURNAL (2019)
Integrated Assessment of the Clinical Performance of GalNAc3-Conjugated 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides: I. Human Volunteer Experience
Stanley T. Crooke et al.
NUCLEIC ACID THERAPEUTICS (2019)
Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled study
Jan Oscarsson et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2018)
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
G. G. Schwartz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
ANGPTL3 Deficiency and Protection Against Coronary Artery Disease
Nathan O. Stitziel et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides
Mark J. Graham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease
F. E. Dewey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The Effects of 2′-O-Methoxyethyl Containing Antisense Oligonucleotides on Platelets in Human Clinical Trials
Stanley T. Crooke et al.
NUCLEIC ACID THERAPEUTICS (2017)
Injection site reactions after subcutaneous oligonucleotide therapy
Leonie van Meer et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Christopher P. Cannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Mutations in the ANGPTL3 Gene and Familial Combined Hypolipidemia: A Clinical and Biochemical Characterization
Ilenia Minicocci et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Exome Sequencing, ANGPTL3 Mutations, and Familial Combined Hypolipidemia
Kiran Musunuru et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase
T Shimizugawa et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
分享论文
